| Ytd | -16.90% | |
| 1y | -11.24% |
| Open | 3.06 | Prev Close | 3.05 | Low | 2.98 | High | 3.08 | Mkt Cap | 583.42M |
| Vol | 3.54M | Avg Vol | 4.04M | EPS | -0.93 | P/E | -3.23 | Forward P/E | -5.14 |
| Beta | 0.07 | Short Ratio | 5.81 | Inst. Own | 56.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 01-20 | Earning | 08-11 | 50-d Avg | 2.90 | 200-d Avg | 3.74 | 1yr Est | 22.86 |
ALT News
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolutio
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol
Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial as
Altimmune NASDAQ: ALT reported positive top-line results from its Phase II RECLAIM trial evaluating
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Altimmune said on Tuesday its experimental drug met the main goal of a mid-stage trial to help pe
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heav
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conferenc
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 da
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set
Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the se
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the compa
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Th
Shares of UiPath Inc. (NYSE: PATH) shares surged in pre-market trading after the company reported up
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl